Clinical Trials Sponsored by Prothena Biosciences Limited

Total 42 results

Prothena Biosciences Limited

Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Amyloidogenic Transthyretin (ATTR) Amyloidosis

United States, Spain, Sweden, Portugal
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

Parkinsons Disease

United States, United Kingdom, Canada, France, Luxembourg, Poland, Spain, Italy, Austria
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Prothena Biosciences Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis (AFFIRM-AL)

Light Chain (AL) Amyloidosis

United States, Korea, Republic of, Australia, Denmark, France, Italy, Spain, Israel, Taiwan, Austria, Canada, Czechia, Germany, Greece, Hungary, Japan, Netherlands, Poland, Portugal, Turkey, United Kingdom, Belgium, Ireland
Prothena Biosciences Ltd.

Terminated

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis (OLE)

AL Amyloidosis

United States
Prothena Biosciences Ltd.

Completed

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (PRONTO)

AL Amyloidosis

United States, Spain, Australia, Germany, United Kingdom, France, Greece, Israel, Italy, Austria
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
GWT-TUD GmbH
Michael J. Fox Foundation for Parkinson's Research; Prothena Biosciences Limited

Completed

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE-PD)

Parkinson's Disease

United States, Germany, Hungary
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
Brii Biosciences Limited

Completed

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

Severe Postpartum Depression

United States
Brii Biosciences, Inc.

Withdrawn

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

COVID-19

China
Kaneq Bioscience Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791

Insulin Resistance | Healthy Volunteers

Canada
Kaneq Bioscience Limited

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Tyligand Bioscience (Shanghai) Limited

Recruiting

TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

China
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis (LC)

Liver Cirrhosis

China
Tyligand Bioscience (Shanghai) Limited

Recruiting

TSN084 Treating Patients With Advanced Malignant Tumors

Malignant Neoplasm

China
Tyligand Bioscience (Shanghai) Limited

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Malignant Neoplasm

United States
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China
Tyligand Bioscience (Shanghai) Limited

Recruiting

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Cancer (With or Without Metastasis)

United States
Brii Biosciences Limited
Vir Biotechnology, Inc.

Active, not recruiting

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection

Singapore, Thailand, Australia, China, Korea, Republic of
Prothena Biosciences Ltd.
Amyloidosis Research Consortium; Amyloidosis Support Groups; Amyloidosis Foundation and other collaborators

Completed

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

COVID-19

China
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

COVID-19

China
Brii Biosciences Limited
TSB Therapeutics (Beijing) CO.LTD

Completed

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198

COVID-19

China
Calithera Biosciences, Inc
Novotech (Australia) Pty Limited

Completed

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

Drug Interaction

Australia
JD Bioscience Inc.
Novotech (Australia) Pty Limited

Enrolling by invitation

First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease

Non-alcoholic Steatohepatitis

Australia
Brii Biosciences Limited
Alnylam Pharmaceuticals; Vir Biotechnology, Inc.

Completed

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Hepatitis B, Chronic

China
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
Sun Pharmaceutical Industries Limited
Moebius Medical Ltd.; Nordic Bioscience Clinical Development (NBCD)

Completed

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

Osteoarthritis of Knee

United States, Denmark, Hong Kong
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaborators

Recruiting

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute | AML Stage, Adult

China
UMC Utrecht
Institut National de la Santé Et de la Recherche Médicale, France; Philips... and other collaborators

Completed

Liquid Biopsies and Imaging in Breast Cancer (LIMA)

Breast Cancer

Netherlands
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); University of Copenhagen; US... and other collaborators

Completed

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
National Institute of Allergy and Infectious Diseases...
Eli Lilly and Company; National Heart, Lung, and Blood Institute (NHLBI); Gla... and other collaborators

Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)

Covid19

United States, Denmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom

Clinical Trials Sponsored by Prothena Biosciences Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations